Korea Launches First Clinical-Grade iPSC Distribution for Research and Therapeutics Development
South Korea’s KDCA has begun distributing the nation’s first clinical-grade induced pluripotent stem cell lines, a move expected to cut costs and speed development of artificial blood and other cell-based therapies.
Key findings
• Korea’s disease agency is starting distribution of clinical-grade induced pluripotent stem cells (iPSCs) for research use.
• The agency says the new cell supply could reduce the time and cost of early cell therapy development.
• South Korea has also established its first clinical-grade iPSC Master Cell Bank (MCB).
The National Institute of Health under the Korea Disease Control and Prevention Agency has developed clinical-grade induced pluripotent stem cells (iPSCs) and is now beginning distribution to domestic research institutions and bio companies.
Get Regen Report in your inbox
Weekly updates on regenerative medicine news, trials, and regulatory moves.
These iPSCs are designed for immediate clinical research use. iPSCs are made by reprogramming ordinary cells, such as skin cells, back into an early developmental state, allowing them to later be turned into different cell types. They can be used in work involving blood components such as red blood cells and platelets, as well as broader cell-based therapeutics.
In this case, “clinical-grade” means the cells were produced under Good Manufacturing Practice (GMP) standards, which are used for pharmaceutical manufacturing and are intended to support the quality and safety requirements for patient-treatment research.
Why this matters
Until now, researchers often had to make these source cells themselves, which added cost and complexity to early-stage development. By supplying standardized cells directly, the government expects to lower that burden and shorten the path toward clinical trials.
The effort came out of the “Cell-Based Artificial Blood Manufacturing and Demonstration Platform” project, which is being pursued jointly by government ministries including the Ministry of Health and Welfare. Artificial blood technology uses stem cells to produce red blood cells or platelets, and is viewed as one possible way to help address blood shortages for transfusion. It is also considered a broader platform technology for cell therapy development.
Cell bank details
The newly established cells were primarily derived from Type O blood, which is associated with fewer transfusion-related rejection reactions. The institute secured 18 cell lines in total, and one of those has been developed into a Master Cell Bank (MCB), a standardized repository intended to provide large numbers of cells of consistent quality for clinical research.
According to the agency, this is the first time a clinical-grade iPSC-based MCB has been established in South Korea.
The government says the broader goal is to support a shift in the country’s bio industry from a generics-centered structure toward therapeutics development, while also building competitiveness in artificial blood and regenerative medicine.
“Establishing a national cell bank is core infrastructure that lowers the entry barrier for regenerative medicine research,” KDCA Commissioner Lim Seung-gwan said. “We will develop it into a global-level cellular resource platform.”
Want to keep up on regenerative medicine? Get the weekly newsletter here.
